These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 12670781

  • 1. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
    Grootendorst DC, Gauw SA, Baan R, Kelly J, Murdoch RD, Sterk PJ, Rabe KF.
    Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
    [Abstract] [Full Text] [Related]

  • 2. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
    Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC, International Study Group.
    Lancet; 2001 Jul 28; 358(9278):265-70. PubMed ID: 11498212
    [Abstract] [Full Text] [Related]

  • 3. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
    Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK.
    Am J Respir Crit Care Med; 2003 Oct 15; 168(8):976-82. PubMed ID: 12816740
    [Abstract] [Full Text] [Related]

  • 4. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
    Rennard SI, Schachter N, Strek M, Rickard K, Amit O.
    Chest; 2006 Jan 15; 129(1):56-66. PubMed ID: 16424413
    [Abstract] [Full Text] [Related]

  • 5. Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
    Murdoch RD, Cowley H, Kelly J, Higgins R, Webber D.
    Pulm Pharmacol Ther; 2002 Jan 15; 15(6):521-7. PubMed ID: 12493339
    [Abstract] [Full Text] [Related]

  • 6. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
    Cazzola M, Santus P, D'Adda A, Pizzolato S, Di Marco F, Centanni S.
    Pulm Pharmacol Ther; 2009 Jun 15; 22(3):177-82. PubMed ID: 19038356
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
    Pauwels R, Joos GF, Fogarty C, Faiferman I, Hirschberg S, Vessey R, Wouters EF.
    Pulm Pharmacol Ther; 2008 Jun 15; 21(2):385-92. PubMed ID: 18023600
    [Abstract] [Full Text] [Related]

  • 9. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
    Norris V, Ambery C.
    Pulm Pharmacol Ther; 2013 Oct 15; 26(5):574-80. PubMed ID: 23524017
    [Abstract] [Full Text] [Related]

  • 10. Cilomilast.
    Schachter EN.
    Drugs Today (Barc); 2006 Apr 15; 42(4):237-47. PubMed ID: 16703120
    [Abstract] [Full Text] [Related]

  • 11. Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.
    Houghton LA, Atkinson W, Whorwell PJ, Morris J, Murdoch RD, Cooper SM, Webber DM, Walls CM.
    Clin Ther; 2006 Apr 15; 28(4):569-81. PubMed ID: 16750468
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 15; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 14. Walking exercise response to bronchodilation in mild COPD: a randomized trial.
    Gagnon P, Saey D, Provencher S, Milot J, Bourbeau J, Tan WC, Martel S, Maltais F.
    Respir Med; 2012 Dec 15; 106(12):1695-705. PubMed ID: 22999808
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.
    Singh D, Abbott-Banner K, Bengtsson T, Newman K.
    Eur Respir J; 2018 Nov 15; 52(5):. PubMed ID: 30166326
    [Abstract] [Full Text] [Related]

  • 17. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
    Giembycz MA.
    Br J Clin Pharmacol; 2006 Aug 15; 62(2):138-52. PubMed ID: 16842388
    [Abstract] [Full Text] [Related]

  • 18. [Effects of salbutamol and ipratropium bromide on arterial blood gases in patients with stable COPD].
    Ozdemir T, Geçkin E, Oğüş C, Cilli A.
    Tuberk Toraks; 2003 Aug 15; 51(2):132-7. PubMed ID: 15143418
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
    Zuwallack R, De Salvo MC, Kaelin T, Bateman ED, Park CS, Abrahams R, Fakih F, Sachs P, Pudi K, Zhao Y, Wood CC, Combivent Respimat Inhaler Study Group.
    Respir Med; 2010 Aug 15; 104(8):1179-88. PubMed ID: 20172704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.